OOOluwatobi Omoworare

Oluwatobi Omoworare

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Oluwatobi Omoworare has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The impact of kidney dysfunction on blood-brain barrier integrity and neurological conditions

    by Nicholas Aderinto, Gbolahan Olatunji, Emmanuel Kokori, Ikponmwosa Ogieuhi, Komolafe Babajide Ayodeji, Victor Oluwatomiwa Ajekiigbe, Muhammadul-Awwal Irodatullah Bisola, Joan Oluwadamilola Ajayi, Chinonyelum Agbo, Oluwatobi Omoworare, et al.

    The kidney–brain axis represents a bidirectional pathophysiological link between chronic kidney disease (CKD), acute kidney injury (AKI), and blood–brain barrier (BBB) dysfunction. CKD affects over 800 million individuals globally and is associated with accelerated cognitive decline, stroke, and neurodegenerative disorders. This review synthesizes evidence that uremic toxins, systemic inflammation, oxidative stress, hormonal dysregulation (erythropoietin deficiency, RAAS activation), and gut dysbiosis converge to impair BBB integrity via tight junction degradation, endothelial activation, and pericyte–astrocyte decoupling. These alterations facilitate neuroinflammation, neurotoxicity, and leukocyte infiltration, contributing to the pathogenesis of stroke, Alzheimer’s disease, Parkinson’s disease, epilepsy, and CKD-associated leukoencephalopathy. Hemodialysis-induced osmotic shifts and sleep fragmentation further exacerbate BBB and glymphatic dysfunction. Preserving BBB integrity through uremic toxin reduction, anti-inflammatory strategies, RAAS inhibition, and lifestyle interventions (e.g., exercise) emerges as a critical therapeutic goal. Future research must prioritize biomarker validation (claudin-5, S100B), neuroimaging correlations, and targeted BBB-protective therapies to mitigate neurological morbidity in renal disease.


  • Open Access

    A review of proton beam therapy’s role in glioma management

    by Nicholas Mbbs Aderinto, Gbolahan Mbbs Olatunji, Emmanuel Mbbs Kokori, Doyin Olatunji, Oluwatobi Mbbs Omoworare, Adetola Emmanuel Mds Babalola, Chimezirim Mbbs Ezeano, Damilare Adewale Mbbs Olusanya, David Timilehin Mbbs Isarinade, Aminat Mbbs Akinoso, et al.

    Gliomas pose significant therapeutic challenges due to limited survival and risks of treatment-related toxicity. Proton beam therapy (PBT) offers a precise radiation delivery method, minimizing damage to healthy brain tissue compared to conventional radiotherapy. This review synthesizes findings from 15 studies (2000–January 2024) from PubMed, Google Scholar, Science Direct, Cochrane Library, and Directory of Open Access Journals. PBT significantly reduces neurocognitive decline and enhances quality of life while achieving comparable or superior survival outcomes across various glioma types, including low-grade gliomas and glioblastomas. Notable benefits include improved verbal memory, stable intellectual functioning, and reduced high-grade toxicity. However, challenges such as neuroendocrine deficiencies and increased radiation necrosis highlight the need for optimized protocols. Future research should focus on comprehensive outcome assessments, proactive management of adverse effects, and improving PBT accessibility through cost reduction and technological advancements. PBT holds transformative potential in glioma management, balancing effective tumor control with preservation of neurological function, positioning it as a valuable neuro-oncology treatment option.


  • Open Access

    Understanding the biological effects of hypoxia in ischemic stroke: implications for rehabilitation and recovery

    by Nicholas Aderinto, Gbolahan Olatunji, Emmanuel Kokori, Bonaventure Ukoaka, Adetola Emmanuel Babalola, Ikponmwosa Jude Ogieuhi, Abdulrahmon Moradeyo, Ismaila Ajayi Yusuf, Apampa Oluwatobiloba Oluwatomisin, Adefusi Temiloluwa Oluwakorede, et al.


  • Open Access

    High-dose vitamin D supplementation in multiple sclerosis: a systematic review of clinical effects and future directions

    by Nicholas Aderinto, Gbolahan Olatunji, Emmanuel Kokori, Ikponmwosa Jude Ogieuhi, Emmanuel Adetola Babalola, Owolabi Samuel, Israel Charles Abraham, Julia Kwape Mimi, Aminnah Oyesomi, Yewande Abigail Adebayo, et al.

    Vitamin D deficiency is common in multiple sclerosis (MS) patients. This review explores the potential benefits and limitations of high-dose vitamin D supplementation in MS management. We reviewed relevant literature on the effects of high-dose vitamin D supplementation on relapse rates, disability progression, quality of life, and MRI markers of disease activity in MS patients. Additionally, we discussed the mechanisms by which vitamin D might influence MS, potential adverse effects, and future research directions. Studies suggest that high-dose vitamin D supplementation may reduce relapse rates and improve MRI markers of disease activity in MS. However, the evidence for its impact on disability progression and quality of life remains inconclusive. Vitamin D’s immunomodulatory properties are well-documented, and its potential for neuroprotection and neurogenesis warrants further investigation. High-dose vitamin D supplementation holds promise as a complementary or disease-modifying therapy for MS. However, further robust research is required to solidify its role in clinical practice. Exploring vitamin D’s multifaceted effects on the immune system, neuroprotection, and neurogenesis paves the way for novel therapeutic strategies to improve the lives of individuals with MS.


  • Open Access

    A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy

    by Gbolahan Mbbs Olatunji, Emmanuel Mbbs Kokori, Israel Charles Mbbs Abraham, Oluwatobi Mbbs Omoworare, Doyin Olatunji, Chimezirim Mbbs Ezeano, Babawale Mbbs Emmanuel Adeoba, Anthony Chidera Mbbs Stanley, Awoyinfa Michael Mbbs Oluwatobiloba, Omidiran Basit Mbbs Oluwademilade, et al.

    Hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis), known as Corino de Andrade disease, is a rare neurodegenerative disorder with a significant global impact characterized by the misfolding of transthyretin (TTR) protein leading to amyloid aggregation, ATTRv amyloidosis, especially with polyneuropathy, poses a considerable challenge in managing its rapid progression and debilitating effects. This mini-review focuses on the recent advancements in the treatment landscape for ATTRv amyloidosis with polyneuropathy, specifically the RNA interference therapeutic Vutrisiran and the ligand-conjugated antisense oligonucleotide Eplontersen. We aim to provide a comprehensive overview of the mechanisms, current evidence from clinical trials, and future directions for these novel therapeutic agents. Vutrisiran and Eplontersen have demonstrated significant clinical efficacy in improving neuropathic impairment, quality of life, and serum TTR levels in various trials. The distinct mechanistic approaches of these therapies, coupled with their acceptable safety profiles, offer promising avenues for addressing the complexities of ATTRv amyloidosis with polyneuropathy. The introduction of Vutrisiran and Eplontersen marks a pivotal moment in the quest for effective therapies against ATTRv amyloidosis with polyneuropathy. While clinical evidence is promising, ongoing research is crucial to deepen mechanistic understanding and address research gaps. Future perspectives include the potential expansion of therapeutic options and a more inclusive approach to cater to the diverse needs of individuals globally. This mini-review provides valuable insights into the evolving landscape of ATTRv amyloidosis management and sets the stage for further exploration in this challenging domain.


  • Open Access

    The potential of smart inhaler for asthma management in Sub-Saharan Africa

    by Emmanuel Kokori, Gbolahan Olatunji, Mubarak Jolayemi Mustapha, Praise Fawehinmi, Adrian Onyia, Oluwatobi Omoworare, Olufemi Akinmeji, Samuel Solomon, Ayobami Olafimihan, Damilola Ologbe, et al.

    An abstract is unavailable. This article is available as a PDF only.